Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Current Assets (2023 - 2025)

Compass Therapeutics' Current Assets history spans 3 years, with the latest figure at $209.8 million for Q4 2025.

  • For Q4 2025, Current Assets rose 58.05% year-over-year to $209.8 million; the TTM value through Dec 2025 reached $209.8 million, up 58.05%, while the annual FY2025 figure was $209.8 million, 58.05% up from the prior year.
  • Current Assets for Q4 2025 was $209.8 million at Compass Therapeutics, down from $221.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $221.1 million in Q3 2025 and bottomed at $106.2 million in Q2 2025.
  • The 3-year median for Current Assets is $156.2 million (2023), against an average of $160.6 million.
  • The largest YoY upside for Current Assets was 58.05% in 2025 against a maximum downside of 30.84% in 2025.
  • A 3-year view of Current Assets shows it stood at $153.9 million in 2023, then fell by 13.73% to $132.8 million in 2024, then surged by 58.05% to $209.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Current Assets are $209.8 million (Q4 2025), $221.1 million (Q3 2025), and $106.2 million (Q2 2025).